Login to Your Account

Pharma: Clinic Roundup

Friday, April 27, 2012
• Shire plc, of Dublin, Ireland, said its Phase II trial of Vyvanse (lisdexamfetamine dimesylate) for adults with binge-eating disorder met its primary endpoint of significantly reducing the number of binge days per week at the two highest of three doses tested.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription